Phase II Study of CT and MRI Brain Imaging Biomarkers to Predict Response to Radiation Therapy in Adults with Brain Metastases

What this Trial Is About

Researchers are studying patients with brain metastases to see how certain imaging biomarkers can predict responses to radiation treatment. This phase II trial focuses on validating these biomarkers using advanced brain imaging techniques. The study aims to improve understanding of how early changes seen on CT and MRI scans relate to treatment outcomes in these patients. Participants will have CT and MRI scans before starting radiation therapy, and again one week after completing radiotherapy. Another MRI scan will be done during the usual 3-month follow-up visit. These imaging procedures are designed to measure biomarkers that might indicate how well the tumor responds to radiation. Patients will be involved in the study for up to two years, during which time researchers will monitor their scans and clinical status. Outcomes measured include tumor response assessments using established criteria RANO and RECIST and progression-free survival. The study also tracks any unexpected or serious side effects related to the treatment over the two-year period.

Brain Imaging Biomarkers in Patients With Brain Metastasis